ASCO: New ‘Armored’ CAR produces significant responses
The “armored” huCART19-IL18 is an anti-CD19 CAR that was further modified to secrete the pro-inflammatory cytokine, interleukin 18 (IL 18). CHICAGO – While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin …